Qube Research & Technologies LTD Ascendis Pharma A/S Transaction History
Qube Research & Technologies LTD
- $91.4 Billion
- Q3 2025
A detailed history of Qube Research & Technologies LTD transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Qube Research & Technologies LTD holds 290,172 shares of ASND stock, worth $59.3 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
290,172
Previous 201,044
44.33%
Holding current value
$59.3 Million
Previous $34.7 Million
66.25%
% of portfolio
0.06%
Previous 0.04%
Shares
11 transactions
Others Institutions Holding ASND
# of Institutions
307Shares Held
64.4MCall Options Held
357KPut Options Held
107K-
Ra Capital Management, L.P. Boston, MA10.3MShares$2.1 Billion35.1% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.26MShares$1.08 Billion4.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.11MShares$1.04 Billion13.88% of portfolio
-
Janus Henderson Group PLC London, X04.32MShares$884 Million0.41% of portfolio
-
Lombard Odier Asset Management (Europe) LTD London, X04.27MShares$873 Million0.89% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $11.4B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...